Renal Denervation: Ultima Ratio or Standard in Treatment-Resistant Hypertension
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Depending on studied populations and applied definitions, the prevalence of treatment-resistant hypertension (rHT) varies from 10% to 15%, but is higher in conditions associated with increased sympathetic drive, such as obesity, obstructive sleep apnea, diabetes or renal dysfunction. The SYMPLICITY studies recently demonstrated that reducing sympathetic tone by intravascular renal denervation (IRD) is feasible in rHT, but did not provide conclusive evidence on the size and durability of the antihypertensive, renal and sympatholytic effects, long-term safety, quality of life, the possibility to relax antihypertensive drug treatment, cost-effectiveness, and benefit in terms of long-term hard cardiovascular-renal outcomes. At the time of writing of this report, 28 IRD trials in various indications were registered at http://www.clinicaltrials.gov, but only seven had a randomized controlled design. In the US, IRD remains an investigational procedure that cannot be used in clinical practice, but in Europe, CE-label certification of electrical safety is permitting to market catheter systems to any interventional facility for regular clinical use. IRD should not be routinely applied as a substitute for the skilful management of resistant patients, which includes documentation of adherence to antihypertensive drugs, implementation of lifestyle measures and the use of recommended combinations of antihypertensive agents at the highest tolerated daily dose. For now, IRD should therefore remain the ultima ratio in adherent patients with severe rHT, in whom all other efforts to reduce blood pressure have failed. IRD should only be offered within a clinical research context at highly skilled tertiary referral centers that participate in international registries constructed independent of the manufacturers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Comparing methods of measurement: why plotting difference against standard method is misleading
Bland, J. M., & Altman, D. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91748-9 · Cited by 2,343
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
de la Sierra, A., Segura, J., Banegas, J. R., Gorostidi, M., de la Cruz, J. J., Armario, P., Oliveras, A., & Ruilope, L. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168948 · Cited by 809
Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904179 · Cited by 772 · cited 1×
“Blood Pressure Measurement Compared with office measurement, ambulatory blood pressure monitoring removes observer bias and measurement error, minimizes the white coat effect and has greater reproducibility, and, therefore, provides a better estimate of a patient’s usual blood pressure and cardiovascular prognosis.(17…”
Background
Cited by
Azizi, M., Sapoval, M., Gosse, P., Monge, M., Bobrie, G., Delsart, P., Midulla, M., Mounier-Véhier, C., Courand, P.-Y., Lantelme, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61942-5 · Cited by 519
Tomaszewski, M., White, C., Patel, P., Masca, N., Damani, R., Hepworth, J., Samani, N. J., Gupta, P., Madira, W., Stanley, A., et al. (2014) · Heart · doi:10.1136/heartjnl-2013-305063 · Cited by 404
New approaches in the treatment of hypertension
Oparil, S., & Schmieder, R. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.303603 · Cited by 276
Xiao, L., Kirabo, A., Wu, J., Saleh, M. A., Zhu, L., Wang, F., Takahashi, T., Loperena, R., Foss, J. D., Mernaugh, R. L., et al. (2015) · Circulation Research · doi:10.1161/circresaha.115.306010 · Cited by 233
Diagnosis and management of resistant hypertension: state of the art
Wei, F.-F., Zhang, Z.-Y., Huang, Q.-F., & Staessen, J. A. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0006-6 · Cited by 39
Self-citation
Metadata
- Authors
- Persu, A., Renkin, J., Thijs, L., & Staessen, J. A.
- Venue
- Hypertension
- Published
- 2012-09
- Volume
- 60
- Issue
- 3
- Pages
- 596-606
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2016518103
- Cited by
- 88
- References
- 19
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal Denervation: Ultima Ratio or Standard in Treatment-Resistant Hypertension. https://app.cochat.ai/papers/10.1161/hypertensionaha.112.195263
- The paper
- Persu, A., Renkin, J., Thijs, L., & Staessen, J. A. (2012). Renal Denervation: Ultima Ratio or Standard in Treatment-Resistant Hypertension. Hypertension. https://doi.org/10.1161/hypertensionaha.112.195263
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.